Perspective | Published:

Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime

Nature Medicine volume 8, pages 12111217 (2002) | Download Citation

Subjects

A historical perspective on atherosclerosis allows us to reflect on the once controversial hypotheses in the field. Plaque formation was once thought to be dependent upon hypercholesterolemia alone, or solely in response to injury. More recently, inflammatory cascades were thought to be at the root of lesion development. A more realistic view may be that atherosclerosis is neither exclusively an inflammatory disease nor solely a lipid disorder: it is both.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Scandinavian Simvistatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvistatin Survival Study (4S). Lancet 344, 1383–1389 (1994).

  2. 2.

    et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333, 1301–1307 (1995).

  3. 3.

    et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. J. Am. Med. Assoc. 279, 1615–1622 (1998).

  4. 4.

    et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335, 1001–1009 (1996).

  5. 5.

    Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. 339, 1349–1357 (1998).

  6. 6.

    MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360, 7–22 (2002).

  7. 7.

    The cholesterol controversy is over. Why did it take so long? Circulation 80, 1070–1078 (1989).

  8. 8.

    The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362, 801–809 (1993).

  9. 9.

    , & Inflammation and atherosclerosis. Circulation 105, 1135–1143 (2002).

  10. 10.

    The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J. Am. Med. Assoc. 251, 365–374 (1984).

  11. 11.

    Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). J. Am. Med. Assoc. 269, 3015–3023 (1993).

  12. 12.

    , , , & Cholesterol reduction yields clinical benefit: Impact of statin trials. Circulation 97, 946–952 (1998).

  13. 13.

    Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J. Am. Med. Assoc. 285, 2486–2497 (2001).

  14. 14.

    , & Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler. Thromb. Vasc. Biol. 22, 1452–1458 (2002).

  15. 15.

    et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler. Thromb. Vasc. Biol. 21, 115–121 (2001).

  16. 16.

    & Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 21, 1712–1719 (2001).

  17. 17.

    Pleiotropic effects of statins and their clinical significance. Am. J. Cardiol. 88, 291–293 (2001).

  18. 18.

    & A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34–47 (1986).

  19. 19.

    & in The Metabolic and Molecular Basis for Inherited Disease (eds. Scriver, C.R., Beaudet, A.L., Sly, W.S. & Valle, D.) 1981–2030 (McGraw-Hill, New York, 1995).

  20. 20.

    & The low-density lipoprotein pathway and its relation to atherosclerosis. Annu. Rev. Biochem. 46, 897–930 (1977).

  21. 21.

    & The distribution and composition of serum lipoproteins in eighteen animals. Comp. Biochem. Physiol. B 40, 489–501 (1971).

  22. 22.

    , & Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler. Thromb. 13, 1814–1821 (1993).

  23. 23.

    , , , & Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353, 265–267 (1991).

  24. 24.

    , , , & Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 68, 231–240 (1987).

  25. 25.

    et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71, 343–353 (1992).

  26. 26.

    , , , & Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J. Clin. Invest. 93, 1885–1893 (1994).

  27. 27.

    , , & An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler. Thromb. 13, 197–204 (1993).

  28. 28.

    et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J. Clin. Invest. 107, 1255–1262 (2001).

  29. 29.

    et al. The combined role of P- and E-selectins in atherosclerosis. J. Clin. Invest. 102, 145–152 (1998).

  30. 30.

    et al. ICAM-1 deficiency reduces atherosclerotic lesions in double-knockout mice (ApoE−/−/ICAM-1−/−) fed a fat or a chow diet. Arterioscler. Thromb. Vasc. Biol. 20, 2630–2635 (2000).

  31. 31.

    et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc. Natl. Acad. Sci. USA 87, 5134–5138 (1990).

  32. 32.

    , , & Expression of the monocyte chemoattractant protein-1 receptor CCR2 is increased in hypercholesterolemia: differential effects of plasma lipoproteins on monocyte function. J. Lipid Res. 40, 1053–1063 (1999).

  33. 33.

    , , & Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394, 894–897 (1999).

  34. 34.

    et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J. Clin. Invest. 103, 773–778 (1999).

  35. 35.

    , , & A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J. Clin. Invest. 101, 353–363 (1998).

  36. 36.

    , & Uptake and degradation of low density lipoprotein by swine arterial smooth muscle cells with inhibition of cholesterol biosynthesis. Biochim. Biophys. Acta 424, 404–421 (1976).

  37. 37.

    , , & Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. USA 76, 333–337 (1979).

  38. 38.

    , , & Purification and characterization of a bovine acetyl low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA 85, 9238–9242 (1988).

  39. 39.

    & Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu. Rev. Biochem. 52, 223–261 (1983).

  40. 40.

    , & Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc. Natl. Acad. Sci. USA 78, 6499–6503 (1981).

  41. 41.

    , , , & Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc. Natl. Acad. Sci. USA 81, 3883–3887 (1984).

  42. 42.

    , , , & Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320, 915–924 (1989).

  43. 43.

    et al. CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem. 268, 11811–11816 (1993).

  44. 44.

    Expression of the acetyl low density lipoprotein receptor by rabbit fibroblasts and smooth muscle cells. Up-regulation by phorbol esters. J. Biol. Chem. 265, 12722–12727 (1990).

  45. 45.

    Transport, interactions and retention of plasma proteins in the intima: the barrier function of the internal elastic lamina. Eur. Heart J 11, 72–81 (1990).

  46. 46.

    & Initiation of atherosclerotic lesions in cholesterol-fed rabbits. II. Selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries. Arteriosclerosis 9, 908–918 (1989).

  47. 47.

    , , & Association of apo B lipoproteins with arterial proteoglycans: Pathological significance and molecular basis. Atherosclerosis 139, 205–222 (1998).

  48. 48.

    et al. Effect of arterial proteoglycans and glycosaminoglycans on low density lipoprotein oxidation and its uptake by human macrophages and arterial smooth muscle cells. Arterioscler. Thromb. 12, 569–583 (1992).

  49. 49.

    et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 417, 750–754 (2002).

  50. 50.

    & The response-to-retention hypothesis of early atherogenesis. Arerioscler. Thromb. Vasc. Biol. 15, 551–561 (1995).

  51. 51.

    , , & Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc. Natl. Acad. Sci. USA 84, 2995–2998 (1987).

  52. 52.

    , & Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J. Clin. Invest. 92, 1004–1008 (1993).

  53. 53.

    , , & Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis 3, 215–222 (1983).

  54. 54.

    , , , & Induction of murine macrophage growth by modified LDLs. Arterioscler. Thromb. 13, 331–337 (1993).

  55. 55.

    & Oxidized low density lipoprotein stimulates aortic smooth muscle cell proliferation. Glycobiology 6, 303–311 (1996).

  56. 56.

    et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc. Natl. Acad. Sci. USA 87, 5134–5138 (1990).

  57. 57.

    et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 344, 254–257 (1990).

  58. 58.

    & in Molecular Basis of Cardiovascular Disease (ed. Chien, K.R.) 458–475 (W.B. Saunders, Philadelphia, 1999).

  59. 59.

    & The role of oxidized lipoproteins in atherogenesis. Free Radic. Biol. Med. 20, 707–727 (1996).

  60. 60.

    et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler. Thromb. Vasc. Biol. 16, 831–842 (1996).

  61. 61.

    et al. The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein. J. Biol. Chem. 275, 9163–9169 (2000).

  62. 62.

    et al. Receptors for oxidized low-density lipoprotein on elicited mouse peritoneal macrophages can recognize both the modified lipid moieties and the modified protein moieties: Implications with respect to macrophage recognition of apoptotic cells. Proc. Natl. Acad. Sci. USA 96, 6347–6352 (1999).

  63. 63.

    et al. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J. Biol. Chem. (2002).

  64. 64.

    et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 103, 117–128 (1999).

  65. 65.

    & Recognition of oxidatively damaged and apoptotic cells by an oxidized low density lipoprotein receptor on mouse peritoneal macrophages: Role of membrane phosphatidylserine. Proc. Natl. Acad. Sci. USA 92, 1396–1400 (1995).

  66. 66.

    et al. Scavenger receptors, oxidized LDL, and atherosclerosis. Ann. NY Acad. Sci. 947, 214–222 (2001).

  67. 67.

    et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394, 284–287 (1998).

  68. 68.

    et al. Paraoxonase and coronary heart disease. Curr. Opin. Lipidol. 9, 319–324 (1998).

  69. 69.

    & Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 105, 2107–2111 (2002).

  70. 70.

    , , & Enhanced macrophage uptake of low density lipoprotein after self-aggregation. Arteriosclerosis 8, 348–358 (1988).

  71. 71.

    & Ultrastructure of the intima in WHHL and cholesterol-fed rabbit aortas prepared by ultra-rapid freezing and freeze-etching. J. Lipid Res. 30, 967–978 (1989).

  72. 72.

    , , & Sphingomyelinase converts lipoproteins from apolipoprotein E knockout mice into potent inducers of macrophage foam cell formation. Arterioscler. Thromb. Vasc. Biol. 20, 2607–2613 (2000).

  73. 73.

    , , , & Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates. Arterioscler. Thromb. 12, 1258–1266 (1992).

  74. 74.

    & The pathogenesis of atherosclerosis (first of two parts). N. Engl. J. Med. 295, 369–377 (1976).

  75. 75.

    & The pathogenesis of atherosclerosis (second of two parts). N. Engl. J. Med. 295, 420–425 (1976).

  76. 76.

    , , & Scanning electron microscopy in the evaluation of endothelial integrity of the fatty lesion in atherosclerosis. Atherosclerosis 25, 125–130 (1976).

  77. 77.

    & Atherosclerosis. the road ahead. Cell 104, 503–516 (2001).

  78. 78.

    et al. The dynamics of progression of coronary atherosclerosis studied in 168 medically treated patients who underwent coronary arteriography three times. Am. Heart J. 117, 296–305 (1989).

  79. 79.

    et al. Process of progression of coronary artery lesions from mild or moderate stenosis to moderate or severe stenosis: A study based on four serial coronary arteriograms per year. Circulation 100, 903–909 (1999).

  80. 80.

    & NF-κB: pivotal mediator or innocent bystander in atherogenesis? J. Clin. Invest. 107, 255–264 (2001).

  81. 81.

    et al. Bioactive phospholipid oxidation products. Free Radic. Biol. Med. 28, 1762–1770 (2000).

  82. 82.

    et al. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272, 13597–13607 (1997).

  83. 83.

    et al. Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J. Clin. Invest. 96, 2322–2330 (1995).

  84. 84.

    et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J. Clin. Invest. 95, 774–782 (1995).

  85. 85.

    et al. Inflammatory platelet-activating factor-like phospholipids in oxidized low density lipoproteins are fragmented alkyl phosphatidylcholines. J. Biol. Chem. 274, 28395–28404 (1999).

  86. 86.

    , , & Regulation of endothelial cell tissue factor expression by minimally oxidized LDL and lipopolysaccharide. Arterioscler. Thromb. 13, 1711–1717 (1993).

  87. 87.

    et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest. 88, 2039–2046 (1991).

  88. 88.

    & Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251, 788–791 (1991).

  89. 89.

    & Oxidized LDL activates fas-mediated endothelial cell apoptosis. J. Clin. Invest. 102, 1682–1689 (1998).

  90. 90.

    et al. Oxidized LDL induces monocytic cell expression of interleukin-8, a chemokine with T-lymphocyte chemotactic activity. Arterioscler. Thromb. 14, 47–53 (1994).

  91. 91.

    et al. LPC in oxidized LDL elicits vasocontraction and inhibits endothelium- dependent relaxation. Am. J. Physiol. 267, H2441–H2449 (1994).

  92. 92.

    , , , & Oxidized low density lipoprotein stimulates collagen production in cultured arterial smooth muscle cells. Atherosclerosis 116, 15–26 (1995).

  93. 93.

    , , , & Oxidized-LDL induced changes in membrane physico-chemical properties and [Ca2+]i of bovine aortic endothelial cells. Influence of vitamin E. Atherosclerosis 114, 185–195 (1995).

  94. 94.

    et al. Dysregulation of monocytic nuclear factor-κB by oxidized low-density lipoprotein. Arterioscler. Thromb. Vasc. Biol. 17, 1901–1909 (1997).

  95. 95.

    et al. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J. Biol. Chem. 274, 11924–11929 (1999).

Download references

Author information

Affiliations

  1. Department of Medicine University of California San Diego, La Jolla, California, USA dsteinberg@ucsd.edu

    • Daniel Steinberg

Authors

  1. Search for Daniel Steinberg in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nm1102-1211

Further reading